UPCOMING COVID-19 VACCINE SET FOR DISTRIBUTION TO WORLD’S MOST REMOTE AND IN-NEED COMMUNITIES

Once approved, ViraCorp will initially be focusing the distribution of its new COVID-19 vaccine within selected regions that are most in-need, including South Africa and South America. This decision has been made in direct response to the global need for equitable access to vaccines and the under-representation of vaccinated individuals among the world's poorest countries.

Created by Lancaster University virologist and ViraCorp’s Chief Scientific Officer, Dr Muhammad Munir, the ViraVac vaccine has been developed in a unique way that allows for easier transportation and administration than current vaccines on the market. The vaccine can be administered either as a nasal spray or a transdermal patch, both of which are also more suitable for use with children and those with needle hysteria.

“Having a vaccination which can be transported easily and administered through a nasal delivery system reduces the heavy infrastructure and training requirements of a vaccination drive and will help ensure the vaccine can reach some of the world’s most remote communities,” said Professor Andy Schofield, Vice Chancellor of Lancaster University.

The ViraVac Vaccine can be manufactured in facilities that have previously been limited exclusively to the production of influenza vaccines, which until now have been unused for approximately 10 months of the year. Once approved, ViraVac will be developed in 12 repurposed facilities across the globe, meaning large dosage numbers can be developed quickly and transported efficiently to the areas that are most in need.

“ViraVac is committed to vaccine equity, as outlined by the World Health Organisation, and to ensuring that vaccines are made readily available for everyone regardless of where they live. Vaccination rates in developing countries have largely fallen behind the global average, and far behind what we’re aiming for. Vaccines which are both easier and cheaper to transport, store, and administer will have unprecedented value to these remote communities.” — Dr Muhammad Munir, Chief Scientific Officer for ViraCorp.

ViraCorp is a British biomedical firm that is on a mission to improve the health outcomes for as many of the world’s population as possible. ViraCorp and its subsidiaries are aiming to lead the fight against viral infections and diseases, while also providing humanitarian aid to the people and places that need it most.